Ahmed F Abdel-Magid
Overview
Explore the profile of Ahmed F Abdel-Magid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
454
Followers
0
Related Specialty
Related Specialty
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdel-Magid A
ACS Med Chem Lett
. 2025 Feb;
16(2):204-206.
PMID: 39967643
The invention in this patent application relates to 2-amino-[1,2,4]triazolo[1,5-]pyridin derivatives represented generally herein as formula 1. These compounds have activities as receptor-interacting protein kinase 1 (RIPK1) inhibitors and may potentially...
2.
Abdel-Magid A
ACS Med Chem Lett
. 2025 Feb;
16(2):207-209.
PMID: 39967637
The invention in this patent application relates to substituted piperidin-2-one derivatives represented generally herein as formula 1. These compounds are activators of AMPK and may be used for the treatment...
3.
Abdel-Magid A
ACS Med Chem Lett
. 2025 Feb;
16(2):210-212.
PMID: 39967628
The invention in this patent application relates to 2-substituted-6-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)isoindolin-1-one derivatives represented herein by formula 1. These compounds possess HDAC6 inhibitory activity and may be useful for the treatment of central...
4.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Dec;
15(12):2085-2087.
PMID: 39691533
The invention in this patent application relates to 1,6-dihydro-7-pyrrolo[2,3-]pyridin-7-one derivatives represented generally by formula 1. These compounds are inhibitors of the E3 ubiquitin ligase, casitas B-lineage lymphoma proto-oncogene-b (CBL-B), and...
5.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Dec;
15(12):2088-2090.
PMID: 39691527
The invention in this patent application relates to -(2-amino-2-oxoethyl)heteroarylcarboxamide derivatives, represented herein generally by formula 1. These compounds are inhibitors of the binding of interleukin 17A (IL-17A) with its receptor...
6.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Sep;
15(9):1424-1426.
PMID: 39291025
The invention in this patent application relates to macrocyclic benzimidazole derivatives represented herein generally by Formula 1. The compounds of Formula 1 are cGAS inhibitors and may potentially provide treatments...
7.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Sep;
15(9):1421-1423.
PMID: 39291023
The invention in this patent application relates to 9,10,11,12-tetrahydro-8-[1,4]diazepino[5',6':4,5]thieno[3,2-]quinolin-8-one derivatives represented herein generally by Formula . These compounds are inhibitors of MK2 kinases and may provide useful treatments for MK2-mediated...
8.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Jun;
15(6):763-765.
PMID: 38894907
The invention in this patent application relates to thiazolo[5,4-]pyridine derivatives represented generally by formula . These compounds are inhibitors of the activity of mucosa-associated lymphoid tissue lymphoma translocation protein 1...
9.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Jun;
15(6):766-768.
PMID: 38894906
The invention in this patent application relates to -(pyrrolidine-3-yl or piperidin-4-yl)acetamide derivatives represented generally by formula 1. These compounds possess activities as somatostatin receptor 4 (SSTR4) agonists and may potentially...
10.
Abdel-Magid A
ACS Med Chem Lett
. 2024 Jan;
15(1):9-11.
PMID: 38229747
The invention in this patent application relates to 1-aminophthalazine derivatives represented generally by formula 1. These compounds are inhibitors of the interaction of the catalytic site of SOS1 with RAS-family...